Table of Contents List of Tables List of Figures Introduction Global Markets Direct Report Coverage Somatostatin Receptor Type 4 (SSTR4) - Overview Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Somatostatin Receptor Type 4 (SSTR4) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Somatostatin Receptor Type 4 (SSTR4) - Companies Involved in Therapeutics Development Crinetics Pharmaceuticals Inc Strongbridge Biopharma plc Somatostatin Receptor Type 4 (SSTR4) - Drug Profiles CNTX-0290 - Drug Profile Product Description Mechanism Of Action R&D Progress NNC-269100 - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize SSTR2 and SSTR4 for Chronic Pain and Neuropathic Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Small Molecules to Agonize SSTR4 for Neuropathic Pain and Chronic Pain - Drug Profile Product Description Mechanism Of Action R&D Progress Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile Product Description Mechanism Of Action R&D Progress veldoreotide - Drug Profile Product Description Mechanism Of Action R&D Progress Somatostatin Receptor Type 4 (SSTR4) - Dormant Products Somatostatin Receptor Type 4 (SSTR4) - Product Development Milestones Featured News & Press Releases May 31, 2016: Strongbridge Biopharma plc Announces Presentation of COR-005 Data at the European Congress of Endocrinology Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study Sep 25, 2013: FDA Grants Orphan Drug Designation for Aspireo’s Somatoprim Jun 18, 2013: Aspireo Reports Start of Further Phase I Study in Healthy Volunteers Apr 03, 2013: Aspireo Pharma Reports Somatoprim Phase IIa Proof Of Concept Results In Acromegaly Jan 07, 2013: Aspireo Pharma Reports Phase Ib Interim Data For Somatoprim Nov 26, 2012: Aspireo Pharma Announces EMA's Committee For Orphan Medicinal Products Recommends Orphan Medicinal Product Designation For Somatoprim Nov 06, 2012: Aspireo Pharma Starts Somatoprim Phase IIa Study In Acromegaly Patients Sep 28, 2012: Evotec And Aspireo Pharma Enter Into Strategic Advisory Agreement For Somatoprim Jun 26, 2012: Somatoprim is a potent agonist of Somatostatin Receptors 2 and 5 Apr 05, 2012: Aspireo Starts Phase I Multi Ascending Dose Study with Somatoprim Feb 26, 2009: DeveloGen Reports Positive Phase I Clinical Trial Results for DG3173 Oct 08, 2008: DeveloGen Announces Completion Of A Phase I Clinical Trial Of DG3173, A Novel Somatostatin Analogue For The Treatment Of Acromegaly Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer

List of Tables Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Indication, H1 2017 Number of Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 Number of Products under Investigation by Universities/Institutes, H1 2017 Products under Investigation by Universities/Institutes, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Pipeline by Crinetics Pharmaceuticals Inc, H1 2017 Pipeline by Strongbridge Biopharma plc, H1 2017 Dormant Products, H1 2017 Dormant Products, H1 2017 (Contd..1), H1 2017 Dormant Products, H1 2017 (Contd..2), H1 2017 List of Figures Number of Products under Development by Stage of Development, H1 2017 Number of Products under Development by Therapy Areas, H1 2017 Number of Products under Development by Top 10 Indications, H1 2017 Number of Products by Stage and Mechanism of Actions, H1 2017 Number of Products by Routes of Administration, H1 2017 Number of Products by Stage and Routes of Administration, H1 2017 Number of Products by Molecule Types, H1 2017 Number of Products by Stage and Molecule Types, H1 2017

Crinetics Pharmaceuticals Inc Strongbridge Biopharma plc